Massachusetts is currently home to 3154 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
INJECTABLE COLD ENERGY THERAPY for the MANAGEMENT of CHRONIC PAIN ASSOCIATED with OSTEOARTHRITIS of the KNEE
Recruiting
The goal of this clinical trial is to evaluate the effectiveness of Neural Ice in the treatment of knee osteoarthritis in adults aged 22-80 years. Participants will attend study visits and complete subject diaries. Participants will be followed for 6 months after study procedure.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
12/17/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Osteoarthritis (OA) of the Knee
Transitioning Together Boston
Recruiting
A randomized controlled trial will be conducted to determine the effects of an adapted family-centered autism transition intervention called Transitioning Together/Juntos en la Transición on meaningful outcomes for families. The study will occur in a safety net hospital setting. The adapted version of this multi-family group psychoeducation intervention is delivered across one individual family joining session and four 2.5 hour multi-family group sessions. The parent and youth groups are held in... Read More
Gender:
ALL
Ages:
Between 14 years and 21 years
Trial Updated:
12/17/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Autism or Autistic Traits, Family Relations
Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Recruiting
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
12/17/2024
Locations: Dana-Farber/Boston Children's Harvard Medical School, Boston, Massachusetts
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Recruiting
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
Recruiting
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Andover Eye Associates, Andover, Massachusetts
Conditions: Allergic Conjunctivitis
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Recruiting
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Recruiting
The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recomm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced Solid Tumors
Epcoritamab in Previously Treated WM
Recruiting
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder
Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunotherapy
Recruiting
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
Recruiting
The goal of this clinical trial is to learn whether IBD patients have better disease outcomes and feel more empowered to manage their condition if they have access to text messaging with their clinical team and if their symptoms are more regularly monitored through text-based surveys. Researchers will compare participants who have access to text-based monitoring, communication and education to participants who have access to text-based education alone. Researchers will also examine if different... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
12/16/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Recruiting
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfa... Read More
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
12/16/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Multiple Sclerosis